IHI:NYE-iShares U.S. Medical Devices ETF (USD)

ETF | Health |

Last Closing

USD 55

Change

-3.75 (-6.38)%

Market Cap

N/A

Volume

1.19M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-04 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-7.85 (-5.48%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-3.63 (-5.43%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-5.17 (-5.08%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-3.74 (-4.74%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-1.08 (-5.42%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-1.54 (-5.79%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-3.32 (-3.41%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-1.41 (-5.32%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-3.29 (-5.80%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-1.08 (-6.59%)

USD 0.01B

ETFs Containing IHI

MSSS Northern Lights Fund Trus.. 9.63 % 0.00 %

-1.68 (-6.42%)

USD 0.10B
ETAC:CA 0.00 % 1.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.74% 57% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.74% 57% F 51% F
Trailing 12 Months  
Capital Gain -4.01% 76% C+ 50% F
Dividend Return 0.42% 38% F 6% D-
Total Return -3.60% 71% C- 42% F
Trailing 5 Years  
Capital Gain 50.55% 71% C- 52% F
Dividend Return 2.98% 47% F 5% F
Total Return 53.53% 67% D+ 41% F
Average Annual (5 Year Horizon)  
Capital Gain 2.07% 43% F 43% F
Dividend Return 2.49% 43% F 35% F
Total Return 0.42% 47% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 22.36% 38% F 47% F
Risk Adjusted Return 11.14% 43% F 28% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.